Liberostin (Cytisinicline)

Liberostin acts on nicotinic acetylcholine receptors to assist individuals attempting to quit tobacco.

• Smoking cessation: reduces nicotine withdrawal symptoms and cravings, supporting quit attempts.
• Nicotine dependence: helps manage dependence by providing partial receptor stimulation, facilitating gradual reduction of nicotine intake.
• Relapse prevention: provides ongoing receptor modulation to lower risk of returning to smoking.
• Adjunct to behavioral therapy: enhances effectiveness of counseling and support programs for quitting smoking.

• Cytisinicline binds selectively to the α4β2 subtype of nicotinic acetylcholine receptors in the central nervous system, acting as a partial agonist. This activity produces modest receptor stimulation that alleviates nicotine withdrawal while simultaneously blocking the full agonist effect of nicotine, thereby reducing cravings and supporting cessation efforts.

Common and serious adverse reactions have been reported with Cytisinicline use.

Common Side Effects

• Nausea: mild stomach upset.
• Headache: transient pain.
• Insomnia: difficulty sleeping.

Serious or Rare Side Effects

• Mood changes: depression or suicidal ideation.
• Severe allergic reaction: rash, swelling, anaphylaxis.
• Cardiovascular events: chest pain or arrhythmia.

When prescribing Liberostin, clinicians should consider several safety precautions.

• Cardiovascular assessment: evaluate history of heart disease before initiating therapy.
• Psychiatric monitoring: watch for mood alterations or suicidal thoughts during treatment.
• Liver function: avoid use in patients with severe hepatic impairment.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Concomitant nicotine products: do not combine with other nicotine replacement therapies without medical guidance.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Cytisinicline may interact with other medicines; awareness of key interactions helps minimize risk.

Major Interactions (Avoid)

• Combined nicotine replacement therapy: may intensify nicotine effects and increase adverse events.
• Other nicotinic agonists (e.g., varenicline): additive stimulation of receptors can raise risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely)

• Alcohol: may enhance dizziness or sedation.
• CNS depressants (e.g., benzodiazepines): monitor for increased drowsiness.
• Antidepressants: observe for mood changes or serotonin syndrome signs.